MBF Therapeutics

Ambler, PA, USA
www.mbftherapeutics.com
Presenter: Thomas Tillett, President & CEO

MBF Therapeutics Inc. (MBFT) is a development-stage veterinary oncology company dedicated to advancing the standard of cancer care for companion animals by commercializing safe, effective and humane therapies for the rapidly evolving, high value veterinary market. MBFT is taking advantage of significant advances in human cancer treatment by adapting therapies proven safe and effective in human clinical studies for use in companion animals.

MBFT will pursue conditional registrations for MBFT-101 under the Minor Use/Minor Species (MUMS) program at FDA and a conditional license for MBFT-102 from USDA-APHIS. Conditional registrations significantly accelerate the time to commercialization and we anticipate that we will have two MBFT-101 products (one for dogs, one for cats) and one MBFT-102 product (for dogs) on the market within three years.

MBFT has secured exclusive licenses for veterinary use of proprietary human therapeutic products for which key patents have been allowed in MBFT’s major markets.

MBFT-101 is a clinical-stage, targeted small molecule therapy consisting of MBF-1569, a proprietary polyamine transport inhibitor, that has been in-licensed from Aminex Therapeutics, and DFMO, a potent inhibitor of ornithine decarboxylase (ODC), for treatment of solid tumors and lymphoma. MBFT-101 targets the two critical sources of intracellular polyamines: (1) DFMO specifically and irreversibly inhibits ODC; and (2) MBF-1569 prevents uptake of polyamines from the intercellular tumor environment. This mechanism effectively starves tumor cells for essential polyamines to shrink and eradicate tumors, but is not deleterious to normal cells.

MBFT 102 is a potent therapeutic vaccine based on technology exclusively licensed from Columbia University. The active molecule is the tumor suppressor/cytokine gene mda-7/IL24, which has demonstrated safety and efficacy in human patients with a variety of advanced cancers including melanoma, breast, colon, head and neck, lymphoma, hepatoma and adrenal carcinoma.